NCT05021328 2025-02-07
Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC
Hubei Cancer Hospital
Phase 1 Completed
Clinical Trials
11 trialsNCT06699576 2024-11-21
ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.
Hansoh BioMedical R&D Company
Phase 1 Not yet recruiting
NCT06331169 2024-08-30
Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer
Fudan University
Phase 1 Recruiting
NCT04967079 2024-04-23
Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients
Shanghai Chest Hospital
Phase 1 Completed
NCT04731038 2021-09-17
Combination Therapy for First Line Treatment of Advanced Cervical Cancer
Ruijin Hospital
Phase 1 Unknown
NCT04764084 2021-02-21
Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors
Peking University Cancer Hospital & Institute
Phase 1 Unknown
NCT03897283 2019-10-30
Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT03910127 2019-10-30
Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT02825563 2019-05-22
A Phase I Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer Patients
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Completed
NCT02622932 2019-04-30
Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Completed
NCT02752516 2017-09-18
A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown